TheraRadar
← Back
Data updated: May 24, 2026

ACCORD BIOPHARMA INC.

Biotech

ACCORD BIOPHARMA INC. is a biotechnology company focused on Gastroenterology, Immunology.

2024
Since
8
Drugs
-
Trials
5
New Drugs (2yr)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Gastroenterology 54%
1 drugs Phase 1: 1
Immunology 46%
1 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • IMULDOSA leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Gastroenterology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling